The immunogenic involvement of miRNA-492 in mycoplasma pneumoniae infection in pediatric patients

Jia, Zhiyi; Sun, Qiwei; Zheng, Yanfei; Xu, Jing; Wang, Yanxia

doi:10.1016/j.jped.2022.07.010

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, miR-509-5p targets TRAF6 to negatively regulate the NF-κB pathway and modulate the inflammatory response in sheep infected with MP [42]. In mononuclear macrophages, miRNA-492 regulates the secretion of immune-inflammatory factors like IL-6 and IL-18, thereby contributing to the development of Mycoplasma pneumonia in children [43]. Additionally, miR-145 targets Smad3 to inhibit the TGF-β/Smad pathway, while miR-146a targets Toll-like receptors' (TLRs) downstream signaling pathways, which are involved in regulating the intrinsic immune response [44].…”

Section: Mirnas In Mmpmentioning

confidence: 99%

Exosomal microRNA/miRNA Dysregulation in Respiratory Diseases: From Mycoplasma-Induced Respiratory Disease to COVID-19 and Beyond

Wang,

Zou,

Zhao

et al. 2023

Cells

View full text Add to dashboard Cite

Respiratory diseases represent a significant economic and health burden worldwide, affecting millions of individuals each year in both human and animal populations. MicroRNAs (miRNAs) play crucial roles in gene expression regulation and are involved in various physiological and pathological processes. Exosomal miRNAs and cellular miRNAs have been identified as key regulators of several immune respiratory diseases, such as chronic respiratory diseases (CRD) caused by Mycoplasma gallisepticum (MG), Mycoplasma pneumoniae pneumonia (MMP) caused by the bacterium Mycoplasma pneumoniae, coronavirus disease 2019 (COVID-19), chronic obstructive pulmonary disease (COPD), asthma, and acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Consequently, miRNAs seem to have the potential to serve as diagnostic biomarkers and therapeutic targets in respiratory diseases. In this review, we summarize the current understanding of the functional roles of miRNAs in the above several respiratory diseases and discuss the potential use of miRNAs as stable diagnostic biomarkers and therapeutic targets for several immune respiratory diseases, focusing on the identification of differentially expressed miRNAs and their targeting of various signaling pathways implicated in disease pathogenesis. Despite the progress made, unanswered questions and future research directions are discussed to facilitate personalized and targeted therapies for patients with these debilitating conditions.

show abstract

Section: Mirnas In Mmpmentioning

confidence: 99%

Exosomal microRNA/miRNA Dysregulation in Respiratory Diseases: From Mycoplasma-Induced Respiratory Disease to COVID-19 and Beyond

Wang,

Zou,

Zhao

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

miRNA, lncRNA and circRNA: targeted molecules with therapeutic promises in Mycoplasma pneumoniae infection

Tian

2023

Arch Microbiol

View full text Add to dashboard Cite

Construction and Validation of an Early Identification Model for Refractory Mycoplasma pneumoniae-Positive Lobar Pneumonia

Zhou,

Tang,

et al. 2024

J Pediatr Infect Dis

View full text Add to dashboard Cite

Objective This study analyzed the relationship between clinical parameters and prognosis in children with Mycoplasma pneumoniae (MP)-positive lobar pneumonia and developed an early identification model. Methods Relevant clinical parameters were collected. Patients were then categorized into two groups based on their length of hospital stay: 116 cases in the refractory group (≥10 days) and 94 cases in the non-refractory group (<10 days). A univariate analysis of variance and binary logistic regression were utilized to develop a predictive model, accompanied by the construction of a nomogram. The model's performance was assessed using receiver operating characteristic (ROC) curves, diagnostic calibration curves, and decision curve analysis (DCA) curves. Furthermore, clinical data from 100 additional cases of MP-positive lobar pneumonia in children treated at other centers were gathered for external validation of the model. Results Binary logistic regression analysis identified four independent risk factors for prolonged disease duration in children with MP-positive lobar pneumonia: erythrocyte sedimentation rate (ESR), globulin, lactate dehydrogenase (LDH), and SF. We constructed a nomogram model based on these risk factors. In the training set, the area under the curve (AUC) was 0.869 (95% CI: 0.822–0.917), with a sensitivity of 68.54% and a specificity of 82.61%. For the test set, the AUC increased to 0.918 (95% CI: 0.866–0.971), demonstrating a sensitivity of 91.67% and a specificity of 78.69%. The DeLong test results indicated that the difference in AUC between the two datasets was not statistically significant (D = − 1.724, p = 0.086). Calibration curve analysis confirmed that the nomogram model exhibited a good fit in both the training set (Hosmer–Lemeshow test, χ2 = 8.120, p = 0.421) and the validation set (Hosmer–Lemeshow test, χ2 = 14.601, p = 0.067). DCA further demonstrated that the model performed significantly across a range of threshold probabilities. Conclusion The nomogram model developed for predicting refractory MP-positive lobar pneumonia in children has significant clinical value and can guide personalized treatment strategies.

show abstract

The immunogenic involvement of miRNA-492 in mycoplasma pneumoniae infection in pediatric patients

Cited by 3 publications

References 27 publications

Exosomal microRNA/miRNA Dysregulation in Respiratory Diseases: From Mycoplasma-Induced Respiratory Disease to COVID-19 and Beyond

Exosomal microRNA/miRNA Dysregulation in Respiratory Diseases: From Mycoplasma-Induced Respiratory Disease to COVID-19 and Beyond

miRNA, lncRNA and circRNA: targeted molecules with therapeutic promises in Mycoplasma pneumoniae infection

Construction and Validation of an Early Identification Model for Refractory Mycoplasma pneumoniae-Positive Lobar Pneumonia

Contact Info

Product

Resources

About